Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →CJC-1295 is a synthetic growth hormone-releasing hormone, or GHRH, analog that signals the pituitary gland to release more growth hormone and IGF-1. It comes as CJC-1295 with DAC, which lasts longer, and CJC-1295 without DAC, also called Modified GRF 1-29. It is not FDA-approved for any indication. [1,2]
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone, a brain signal that tells the pituitary gland to release growth hormone. In early human research, CJC-1295 raised growth hormone and IGF-1 for several days, but it also caused side effects such as injection-site reactions and flushing, and it is not FDA-approved for any indication. [1,2]
The GHRH analog explained
A GHRH analog is a lab-made peptide designed to act like the body’s own GHRH. CJC-1295 is also called a growth hormone secretagogue because it stimulates the body to release growth hormone rather than replacing growth hormone directly. This hormone pathway can affect IGF-1, fluid balance, glucose handling, and soft-tissue growth, so clinician screening is important. [1,6]
CJC-1295 with DAC vs. without DAC (Modified GRF 1-29)
CJC-1295 with DAC, sometimes called DAC:GRF, uses albumin bioconjugation through a drug affinity complex to stay in circulation longer. CJC-1295 without DAC is often called Modified GRF 1-29; it is shorter acting and discussed in peptide practice, but it is also not FDA-approved for any indication. [1,2]
| Form | Also called | Main difference | FDA status | Safety note |
|---|---|---|---|---|
| CJC-1295 with DAC | DAC:GRF | Designed to bind albumin and extend exposure; one early study reported a half-life of about 5.8 to 8.1 days. | Not FDA-approved for any indication. [1,2] | Longer exposure may mean longer-lasting side effects or lab changes; clinician monitoring is needed. [1,6] |
| CJC-1295 without DAC | Modified GRF 1-29 | Shorter-acting GHRH analog discussed in research and peptide practice. | Not FDA-approved for any indication. [2] | Shorter exposure does not remove risks such as injection reactions, hormone changes, swelling, or glucose effects. [2,6] |
How does CJC-1295 work in the body?
CJC-1295 works by activating the GHRH receptor pathway at the pituitary gland, which can increase pulses of growth hormone and raise IGF-1. In one early human study, a single injection increased growth hormone and IGF-1 for several days, but reported side effects included injection reactions, flushing, and headache; people with conditions affected by GH or IGF-1 need medical review. [1,6]
Effect on growth hormone and IGF-1
Growth hormone is released by the pituitary gland in pulses, often during sleep. IGF-1, or insulin-like growth factor 1, is made mostly in the liver in response to growth hormone and helps carry many growth-hormone signals in the body. Too much activity in this pathway can be linked with swelling, joint discomfort, carpal-tunnel-like symptoms, and glucose changes, which is why labs may be used in clinical care. [1,6]
How it differs from injected HGH
Human growth hormone, or HGH, is the hormone itself. CJC-1295 is not HGH; it is a signal that may prompt the body to release more of its own growth hormone. FDA-approved HGH products have specific approved uses and warnings, including risks related to glucose intolerance, fluid retention, intracranial hypertension, and use in people with active malignancy; CJC-1295 does not have an FDA-approved label defining approved uses, dosing, or safety monitoring. [2,6]
Why is CJC-1295 often paired with ipamorelin?
CJC-1295 and ipamorelin are commonly discussed together because they act on related but different growth-hormone signaling pathways. CJC-1295 is a GHRH analog, while ipamorelin is a ghrelin receptor, or GHS-R1a, agonist studied as a growth hormone secretagogue; neither peptide is FDA-approved for any indication, and combination-specific safety trials are limited. [2,3]
The GHRH plus ghrelin receptor synergy
The theory is that a GHRH signal and a ghrelin-receptor signal may support growth-hormone pulses through separate receptors. Studies of growth hormone secretagogues show that this pathway can raise growth hormone, but higher hormone signaling can also cause fluid retention, numbness or tingling, appetite changes, and glucose changes in some settings. [3,6]
What the combination is used for
Clinics may discuss the CJC-1295 and ipamorelin stack for body composition, recovery, sleep quality, or healthy-aging goals, but these uses are research-stage and are not FDA-approved indications. Any possible benefit must be weighed against side effects, lack of large combination trials, and contraindications such as active cancer, certain pituitary disorders, pregnancy, or uncontrolled metabolic disease. [2,3,6]
What benefits do people report from CJC-1295?
CJC-1295 is often discussed for possible changes in body composition, recovery, sleep, and energy, but strong patient-outcome data are limited. Early studies show hormone changes, not guaranteed real-world results; side effects and contraindications still apply, and individual results vary. [1,6]
Body composition and recovery
Growth hormone and IGF-1 are involved in lean tissue, fat metabolism, and repair signaling, so researchers have studied the GH axis in body-composition conditions. That does not mean CJC-1295 is proven for muscle gain, recovery, or fat loss. Possible GH-axis side effects include swelling, joint discomfort, glucose changes, and IGF-1 changes, and people with certain cancer, pituitary, or metabolic risks may not be candidates. [1,6]
Sleep and energy
Growth hormone release is linked with sleep timing, so some people ask whether GH-axis peptides may support sleep or energy. These reports are not proof that CJC-1295 improves sleep, and side effects such as headache, flushing, swelling, or tingling can affect how someone feels day to day. [1,6]
What the research actually shows
The best human evidence for CJC-1295 shows that it can raise growth hormone and IGF-1 in small early trials. In Teichman et al. (2006), healthy adults received single subcutaneous CJC-1295 doses of 30, 60, 125, or 250 μg/kg, and GH and IGF-1 rose for several days; CJC-1295 is not FDA-approved for this or any other use, and the study does not prove long-term benefits for muscle, sleep, recovery, or longevity. [1,2]
What are the side effects and risks of CJC-1295?
CJC-1295 side effects reported or biologically plausible from GH-axis stimulation include injection-site reactions, flushing, headache, dizziness, fluid retention, joint discomfort, numbness or tingling, and changes in glucose or IGF-1. In the early CJC-1295 study, no serious adverse events were reported, but the study was small and not designed to prove long-term safety. [1,6]
Common reported effects
- Injection-site redness, itching, swelling, or pain. [1]
- Flushing, warmth, headache, or lightheadedness. [1]
- Fluid retention, swelling, joint discomfort, or carpal-tunnel-like symptoms, which are known concerns with growth hormone pathway activation. [6]
- Possible changes in blood sugar or insulin sensitivity, especially in people with diabetes risk. [6]
- Changes in IGF-1 levels that may require lab monitoring. [1,6]
Clinical trial safety history
Early CJC-1295 research included a small number of healthy adults and showed dose-related hormone increases. Small short-term studies can miss rare or delayed harms, so they cannot answer whether long-term use is safe for broad patient groups. [1]
Who should avoid it
A licensed clinician may advise against GH-axis peptides for people who are pregnant or breastfeeding, have active cancer, have a history of certain tumors, have untreated pituitary disease, have high IGF-1, have severe illness, or have poorly controlled diabetes. FDA-approved growth hormone labels warn about risks in several of these areas, and CJC-1295 does not have an FDA-approved label to define safe use. [2,6]
Does CJC-1295 affect testosterone or other hormones?
CJC-1295 mainly targets the growth hormone and IGF-1 pathway, not testosterone directly. Some people ask about testosterone because sleep, training, body composition, and hormone systems overlap, but CJC-1295 is not an FDA-approved testosterone treatment and should not be used as a substitute for evaluation of low testosterone symptoms. [1,2]
GH-axis changes may interact with other endocrine signals, including thyroid, glucose, and sex-hormone systems. That is why clinicians may review symptoms, medications, medical history, and labs before considering any peptide plan; benefits are uncertain, and side effects or contraindications may make it inappropriate. [6,7]
How is CJC-1295 dosed and administered?
CJC-1295 dosing should only be set by a licensed clinician because CJC-1295 is not FDA-approved and has no FDA-reviewed dosing instructions. In Teichman et al. (2006), healthy adults received single subcutaneous doses of 30, 60, 125, or 250 μg/kg CJC-1295; the study reported a half-life of about 5.8 to 8.1 days, but this was a research protocol, not patient instructions. [1,2]
With DAC vs. without DAC dosing patterns
CJC-1295 with DAC was designed for longer exposure through albumin binding, while CJC-1295 without DAC, or Modified GRF 1-29, is shorter acting. Because neither form is FDA-approved, there is no FDA-reviewed dose, schedule, maximum duration, or monitoring plan for wellness, recovery, sleep, or body-composition goals. [1,2]
Injection basics
CJC-1295 is commonly discussed as a subcutaneous injection in research and compounding contexts. Injection technique, storage, sterile handling, and adverse-effect monitoring should come from the dispensing pharmacy and licensed clinician, because unsafe injection practices can cause infection, dosing errors, or tissue irritation. [8,9]
Is CJC-1295 FDA-approved or legal?
CJC-1295 is not FDA-approved for any indication. Regulatory status is evolving: CJC-1295 is currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026; check FDA.gov for the latest before relying on availability. [2,10]
Regulatory status
A peptide can be legal in one narrow setting and not allowed in another. For CJC-1295, the key questions are whether the substance may be used in compounding, whether a patient-specific prescription is valid, whether state law allows dispensing, and whether the pharmacy follows applicable quality rules. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before dispensing. [8,9]
The FDA bulk substances list and compounding rules
A 503A compounding pharmacy is a state-licensed pharmacy that may prepare patient-specific compounded medications when legal requirements are met, including a valid prescription. The FDA bulk drug substances list process matters because it can affect whether a substance may be used by 503A pharmacies. [8,10]
CJC-1295 has appeared in FDA regulatory discussions restricting or reviewing compounded use, so patients should avoid gray-market products and confirm current status through licensed channels. No existing Chia internal-link target list was provided for this draft, so internal links should be added before publication if relevant pages are available. [8,10]
How can you get CJC-1295 safely through a licensed provider?
CJC-1295 access should start with a licensed clinician, not a social-media seller or research-chemical website. A clinician can review medical history, medications, contraindications, goals, labs such as IGF-1 or glucose markers when appropriate, and the current legal status before deciding whether any peptide is appropriate. [6,8]
If a prescription is appropriate and legally available, it may be filled through a licensed 503A compounding pharmacy that prepares patient-specific medications. Chia is one telehealth option that can connect eligible patients with clinician-reviewed access to compounded longevity peptides when allowed by current rules, with pharmacy quality checks and ongoing follow-up. [8,9]
3-min quiz
Learn about clinician-reviewed peptide options
If you are exploring growth-hormone-related peptides, a clinical evaluation can help clarify eligibility, labs, risks, and legal availability.
How does CJC-1295 compare with sermorelin, tesamorelin, ipamorelin, and HGH?
CJC-1295 vs sermorelin vs tesamorelin often comes down to receptor target, duration, FDA status, and safety monitoring. Tesamorelin is FDA-approved for a specific HIV-related lipodystrophy use, while CJC-1295, sermorelin as currently compounded, and ipamorelin are not FDA-approved for anti-aging, sleep, recovery, or muscle-building uses. [2,4,5]
| Option | What it is | FDA status | Why people ask about it | Key safety limits |
|---|---|---|---|---|
| CJC-1295 with DAC | Longer-acting GHRH analog and growth hormone secretagogue. | Not FDA-approved for any indication. [2] | Studied for raising growth hormone and IGF-1. [1] | Injection reactions, flushing, headache, fluid retention, glucose or IGF-1 changes; long-term safety is not established. [1,6] |
| Modified GRF 1-29 | Shorter-acting CJC-1295 without DAC, also a GHRH analog. | Not FDA-approved for any indication. [2] | Discussed when shorter GH signaling is desired in research or clinical practice. | Similar GH-axis concerns; no FDA-approved label for dosing or monitoring. [2,6] |
| Ipamorelin | Ghrelin receptor, or GHS-R1a, agonist and growth hormone secretagogue. | Not FDA-approved for any indication. [2,3] | Often paired with GHRH analogs in peptide practice. | Limited combination-specific data; possible appetite, fluid, glucose, or hormone-related effects. [3,6] |
| Sermorelin | GHRH analog historically studied for growth hormone deficiency. | No current FDA-approved sermorelin product is marketed for anti-aging or wellness use. [2] | Discussed as a shorter-acting GH-axis peptide. | Requires clinician review; not approved for longevity, recovery, or muscle-building claims. [2,6] |
| Tesamorelin | GHRH analog. | FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. [4,5] | Sometimes compared because it acts on the GH axis. | Label warnings include malignancy risk, glucose intolerance, fluid retention, and hypersensitivity. [5] |
| Human growth hormone | The hormone itself, given as recombinant HGH. | FDA-approved products exist for specific diagnoses, not general anti-aging. [6] | Used for confirmed growth hormone deficiency and other labeled uses. | Warnings include glucose intolerance, edema, intracranial hypertension, and contraindications in certain cancers or acute critical illness. [6] |
What peptides stack well with CJC-1295?
CJC-1295 stacks are commonly combined in clinical and research practice, but they are not proven protocols and are not FDA-approved for longevity, sleep, recovery, or body-composition treatment. Combination use can increase uncertainty, side effects, cost, and monitoring needs, so it should only be discussed with a licensed clinician. [2,3,6]
- CJC-1295 plus ipamorelin: the rationale is GHRH-receptor signaling plus ghrelin-receptor signaling, which may support growth-hormone pulses through different pathways. The caveat is that combination-specific human safety data are limited, and both peptides are not FDA-approved for any indication. [2,3]
- CJC-1295 plus sermorelin: both act on the GHRH pathway, so pairing may be redundant rather than complementary. The caveat is overlapping GH-axis effects, including possible IGF-1, glucose, swelling, or numbness changes. [2,6]
- CJC-1295 plus tesamorelin: both are GHRH analogs, but tesamorelin has a narrow FDA-approved use in HIV-related lipodystrophy and is not a general wellness peptide. Combining GH-axis agents may raise safety concerns and should not be done without specialist oversight. [4,5,6]
CJC-1295 signals the pituitary gland through the GHRH pathway, which can raise growth hormone and IGF-1 levels in early human research. It is not FDA-approved, and possible side effects include injection reactions, flushing, headache, fluid retention, and glucose or IGF-1 changes. [1,2,6]
No. HGH is human growth hormone itself. CJC-1295 is a peptide signal that may prompt the body to release more of its own growth hormone. FDA-approved HGH products have specific labeled uses and warnings; CJC-1295 has no FDA-approved indication or FDA-reviewed dosing label. [2,6]
CJC-1295 with DAC uses a drug affinity complex to bind albumin and extend exposure; one early study reported a half-life of about 5.8 to 8.1 days. CJC-1295 without DAC is often called Modified GRF 1-29 and is shorter acting. Both are not FDA-approved for any indication. [1,2]
They act on different receptors involved in growth hormone release: CJC-1295 on the GHRH pathway and ipamorelin on the ghrelin receptor pathway. This pairing is discussed in peptide practice, but it is not FDA-approved and lacks large combination-specific safety trials. [2,3]
Some people report interest in recovery, body composition, sleep, or energy, but the strongest CJC-1295 evidence mainly shows hormone changes in small early studies. It does not prove reliable muscle or sleep benefits, and side effects and contraindications still matter. Individual results vary. [1,6]
CJC-1295 mainly affects the growth hormone and IGF-1 pathway, not testosterone directly. It is not an FDA-approved treatment for low testosterone, and symptoms that suggest low testosterone should be evaluated with appropriate labs and clinician review. [1,2]
No. CJC-1295 is not FDA-approved for any indication. Its compounding status is evolving, including FDA review and PCAC discussion of 503A Bulks List issues, so patients should check current FDA guidance and use only licensed medical channels. [2,10]
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides whether any medication or peptide is appropriate, legal, and safe for that patient.
3-min quiz
Talk with a clinician before considering CJC-1295
A clinician can review your goals, health history, labs, contraindications, and current legal availability before any peptide is considered.
References
- 1.Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- 2.U.S. Food and Drug Administration. FDA Drug Compounding: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, 2026.
- 3.Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- 4.Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007.
- 5.U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin) prescribing information, 2024.
- 6.U.S. Food and Drug Administration. GENOTROPIN (somatropin) prescribing information, 2024.
- 7.Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2016.
- 8.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
- 9.United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations, 2023.
- 10.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials and Announcements, 2026.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
